Clinical Utility Evidence for TissueCypher®

Not Applicable

Completed

• Conditions: Barrett Esophagus; Gastro-Intestinal Disorder
• Interventions: Other: Educational materials for TissueCypher

• Registration Number: NCT05200325
• Lead Sponsor: Qure Healthcare, LLC

Brief Summary

Cernostics has developed a new diagnostic test, and this study will measure how gastroenterologists and foregut surgeons make diagnostic and treatment decisions when presented with different information in the context of simulated clinical cases. The results of this study could contribute to improved quality of care for patients by encouraging better care practices and adherence to evidence-based guidance. The data from this study will be provided to all participating physicians and submitted to a national journal for publication. The study plans to enroll up to 249 physicians.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-06
• Study First Submitted: 2021-12-09
• Primary Completion: 2021-12-15
• Study Completion: 2021-12-15
• Study First Submitted QC: 2022-01-06
• Study First Posted: 2022-01-20
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-30
• Last Update Posted: 2023-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 280

Inclusion Criteria

• Board-certified gastroenterologist or GI surgeon for at least two years
• Averages at least 20 hours per week of clinical and patient care duties over the last six months
• performs either diagnostic endoscopy, interventional endoscopy, upper GI surgery, or bariatric surgery
• practicing in the US
• english speaking
• access to the internet
• informed and voluntarily consented to be in the study

Exclusion Criteria

• non-English speaking
• unable to access the internet
• not practicing in the US
• not averaging at least 20 hours per week of clinical or patient care duties over the last six months
• does not perform either diagnostic endoscopy, interventional endoscopy, upper GI surgery, or bariatric surgery
• does not voluntarily consent to be in the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention Group 1	Educational materials for TissueCypher	Intervention group 1 receives educational materials about the TissueCypher diagnostic test. These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report. This intervention group is then forced to use the test results in treating their simulated patients.
Intervention Group 2	Educational materials for TissueCypher	Intervention group 2 receives educational materials about the TissueCypher diagnostic test. These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report. This intervention group then gets to decide whether or not they want to use the TissueCypher test results for their simulated patients.

Primary Outcome Measures

Name	Time	Method
CPV-measured evidence based management decisions	4 months	Evidence-based management decisions based on patient's TissueCypher® test result: Once the intervention group is exposed to the intervention, education materials on the TissueCypher (a validated diagnostic test for predicting risk progression of BE patients), the scores are measured, on a scale of 0% to 100% from round 1 (pre-exposure) to round 2 (post-exposure) and observe how the evidence-based TissueCypher results influence physicians' management decisions.
CPV-measured cost savings	1 month	Change in cost of BE-related care. (This cost is modeled in part by measuring differential rates of endoscopic work up/interventions/levels of care selected by each arm, and multiplying by average Medicare reimbursement rates for these workups/interventions/levels of care. The cost is also modeled by examining average per annum costs for patients suffering from BE, and multiplying by the percent of patients whose workup or therapeutic management is significantly reduced following the intervention.)
Clinical Performance and Value (CPV)-measured change in physician behavior	4 months	Change in the overall and the diagnostic and treatment evidence-based quality scores in the CPV patient simulations: difference-in-differences regression analysis between the control and the intervention groups' diagnosis and treatment of risk progression in patients with Barrett's esophagus, as measured by the participants diagnostic and treatment CPV case domain scores. In each domain of a CPV (history, physical exam, workup, diagnosis and treatment), participants' care recommendations are evaluated against evidence-based care scoring criteria which can sum from 0 to a high potential score of up to 100 percent in each domain, where higher scores mean better outcomes.

Secondary Outcome Measures

Name	Time	Method
CPV-measured baseline levels of variation	4 months	Participants completing the simulated cases, or CPVs, receive scores, on a scale from 0% to 100%, based upon the quality of care they provide. This measure will assess the baseline levels of variation in the care of pain patients among all participants, including by use case types. Baseline levels of variation will be measured in the surveillance, management and treatment of patients with Barrett's esophagus among all participants
CPV-measured use case analysis	4 months	Difference in the overall, and the diagnostic and treatment quality scores between control and intervention participants. Diagnostic and treatment scores are calculated as the percent correct on CPVs, and the overall score is an average score of the subcategory scores (percent correct). The score is reported on a scale from 0% to 100%. This will be examined for each of the use cases to determine in which case(s) CPV scores most improved.

Trial Locations

Locations (1)

QURE Healthcare; 🇺🇸 San Francisco, California, United States